RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells)
Big Pharma companies with ADCs have seen ONCY data's from the PDAC arm of the GOBLET study (pelareorep + chemotherapy + immune checkpoint inhibitor - atezolizumab), that was presented on October 2023 showed a 62% objective response rate (ORR), 7.2 months of median progression-free survival (mPFS), interim median overall survival (mOS) of 10.6 months, and expansion of both pre-existing and new T-cell clones.
ONCY's Phase 2 Bracelet-1 in advanced/metastatic breast cancer demonstrated that pelareorep is effective as a monotherapy in combination with the standard of care of chemotherapy versus standard of care alone. This Phase 2 study demnstrates that ONCY's pelareorep can be effectively combined with an ADC carrying a chemotherapeutical payload.
ONCY's Phase 2 AWARE-1 biomarker study prepared the way for the next wave of immunotherapeutic advances.
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=34100933
Since pelareorep has been proven to activate TiLs, specifically CD8+ dendritic cells, and has shown it capability to remodels the tumor microenvironment, which both facilitates and synergizes the addition of an immune checkpoint inhibitor, the combination of pelareorep + immune checkpoint inhibitor is ready for combination with an ADC carrying a chemotherapeutical payload.